10 Comstock
BioDirection Inc.
Point-of-care blood test for traumatic brain injury
BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injury. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.
More from Archive
More from Medtech Insight
• By
Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.
• By
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
• By
Communication with patients has become a particularly crucial factor for investors, payers, and other healthcare decision-makers in a hostile market environment.